

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <b>Hull Hans</b> <hr/> (Last) (First) (Middle) <b>C/O PLIANT THERAPEUTICS, INC.</b> <b>260 LITTLEFIELD AVENUE</b> <hr/> (Street) <b>SOUTH SAN FRANCISCO CA 94080</b> <hr/> (City) (State) (Zip)			2. Issuer Name and Ticker or Trading Symbol <b>PLIANT THERAPEUTICS, INC. [ PLRX ]</b>			5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <b>Chief Business Officer</b>		
3. Date of Earliest Transaction (Month/Day/Year) <b>08/03/2023</b>			6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person					
4. If Amendment, Date of Original Filed (Month/Day/Year)			Rule 10b5-1(c) Transaction Indication <input checked="" type="checkbox"/> Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.					

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	08/03/2023		S <sup>(1)</sup>		13,069	D	\$20 <sup>(2)</sup>	206,114	D	
Common Stock	08/03/2023		M		1,800	A	\$2.08	207,914	D	
Common Stock	08/03/2023		S <sup>(1)</sup>		1,800	A	\$20 <sup>(3)</sup>	206,114	D	
Common Stock	08/04/2023		M		8,791	A	\$2.08	214,905	D	
Common Stock	08/04/2023		S <sup>(1)</sup>		20,050	D	\$20.01 <sup>(3)</sup>	194,855	D	
Common Stock								3,821	I	See footnote <sup>(4)</sup>
Common Stock								13,985	I	See footnote <sup>(5)</sup>
Common Stock								13,985	I	See footnote <sup>(6)</sup>

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Common Stock (Right to Buy)	\$2.08	08/03/2023		M		1,800		(7)	03/31/2028	Common Stock	1,800	\$0.00	40,158	D	
Common Stock (Right to Buy)	\$2.08	08/04/2023		M		8,791		(7)	03/31/2028	Common Stock	8,791	\$0.00	31,367	D	

**Explanation of Responses:**

- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 3, 2023.
- The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from \$20.00 to \$20.01, inclusive. The Reporting Person undertakes to provide Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4.
- The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from \$20.00 to \$20.08, inclusive. The Reporting Person undertakes to provide Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) to this Form 4.
- The shares are held by The Sloger Hull Family Trust. The Reporting Person and his spouse serve as trustees for the trust. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for the purposes of Section 16 or for any other purpose.
- The shares are held by a trust for the Reporting Person's minor child ("Child A Trust"). The Reporting Person and his spouse serve as trustees for Child A Trust. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

6. The shares are held by a trust for the Reporting Person's minor child ("Child B Trust"). The Reporting Person and his spouse serve as trustees for Child B Trust. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

7. On January 24, 2019, the Reporting Person was granted stock options, the vesting of which was subject to the achievement of pre-established performance criteria which were achieved, and all of which were subject to the Reporting Person's continuous service to the Issuer.

**Remarks:**

/s/ Mike Ouimette, attorney-in-  
fact 08/07/2023

\*\* Signature of Reporting Person      Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**